13 D Management LLC Amarin Corp Plcuk Transaction History

13 D Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.63 - $1.07 $557,430 - $946,747	-884,811 Reduced 97.07%	26,696 $18,000
Q1 2024 May 15, 2024	BUY	$0.82 - $1.35 $846 - $1,393	1,032 Added 0.11%	911,507 $811,000
Q4 2023 Feb 14, 2024	SELL	$0.66 - $0.91 $390,193 - $537,993	-591,202 Reduced 39.37%	910,475 $792,000
Q3 2023 Nov 14, 2023	SELL	$0.85 - $1.43 $2.19 Million - $3.69 Million	-2,579,723 Reduced 63.21%	1,501,677 $1.38 Million
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.49 $95,760 - $127,395	-85,500 Reduced 2.05%	4,081,400 $4.86 Million
Q1 2023 May 15, 2023	BUY	$1.19 - $2.19 $2.36 Million - $4.34 Million	1,980,000 Added 90.54%	4,166,900 $6.25 Million
Q4 2022 Feb 14, 2023	BUY	$1.07 - $1.34 $427,679 - $535,598	399,700 Added 22.36%	2,186,900 $2.65 Million
Q3 2022 Nov 14, 2022	SELL	$1.09 - $1.67 $404,390 - $619,570	-371,000 Reduced 17.19%	1,787,200 $1.95 Million
Q2 2022 Aug 15, 2022	BUY	$1.13 - $3.69 $151,646 - $495,198	134,200 Added 6.63%	2,158,200 $3.22 Million
Q1 2022 May 16, 2022	BUY	$2.85 - $3.73 $5.77 Million - $7.55 Million	2,024,000 New	2,024,000 $6.66 Million

177

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $222M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of 13 D Management LLC, based on Form 13F filings with the SEC.

Stay updated on 13 D Management LLC with notifications on news.